Denali Therapeutics (DNLI) Current Deferred Revenue (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Current Deferred Revenue data on file, last reported at $1.3 million in Q2 2023.

• Current Deferred Revenue for Q2 2023 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $1.3 million (changed N/A YoY), and the FY2022 annual result was $290.1 million, up 939.06% from the prior year.
• Current Deferred Revenue slipped to $1.3 million in Q2 2023 per DNLI's latest filing, from $288.9 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $290.1 million in Q4 2022 and troughed at $23000.0 in Q3 2022.
• A 5-year average of $51.1 million and a median of $21.3 million in 2019 frame the typical range for Current Deferred Revenue.
• On a YoY basis, Current Deferred Revenue climbed as much as 939.06% in 2022 and fell as far as 98.26% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $18.7 million in 2019, then grew by 6.27% to $19.9 million in 2020, then jumped by 40.18% to $27.9 million in 2021, then surged by 939.06% to $290.1 million in 2022, then sank by 99.55% to $1.3 million in 2023.
• Business Quant data shows DNLI's Current Deferred Revenue at $1.3 million in Q2 2023, $288.9 million in Q1 2023, and $290.1 million in Q4 2022.